Alnylam Pharmaceuticals (ALNY) Other Non Operating Income (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has 18 years of Other Non Operating Income data on file, last reported at $273000.0 in Q2 2026.

• Quarterly Other Non Operating Income fell 96.92% year-over-year to $273000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$81.5 million (up 11.69% YoY) and the FY2025 annual result came in at $5.2 million, up 102.88% from the prior year.
• Other Non Operating Income improved to $273000.0 in Q2 2026, from -$4.3 million in the prior quarter.
• In the past five years, Other Non Operating Income ranged from a high of $9.2 million in Q1 2025 to a low of -$80.8 million in Q4 2024.
• A 5-year average of -$30.1 million and a median of -$24.9 million in 2023 frame the typical range for Other Non Operating Income.
• Annual changes were most pronounced in 2023 — Other Non Operating Income plunged 691.56% — and 2025, when it surged 163.19%.
• Tracing ALNY's Other Non Operating Income over 5 years: stood at -$2.6 million in 2022, then sank by 691.56% to -$20.4 million in 2023, then plunged by 297.26% to -$80.8 million in 2024, then surged by 95.84% to -$3.4 million in 2025, then soared by 108.12% to $273000.0 in 2026.
• The last three Other Non Operating Income figures came in at $273000.0 (Q2 2026), -$4.3 million (Q1 2026), and -$3.4 million (Q4 2025), per Business Quant data.